Kisspeptin Injection

Kisspeptin injection, as an active peptide fragment encoded by the KISS1 gene, forms a signaling axis through its specific receptor GPR54 (KISS1R) and plays a central regulatory role in embryonic kidney development. Research has shown that this signaling axis induces the expression of BMP2 (bone morphogenetic protein 2) gene by activating NFATc4 transcription factor.

BMP2 is a key signaling molecule for kidney development, which can promote the differentiation of renal mesenchymal cells into renal epithelial cells and regulate the formation of renal unit structure.

Experiments have shown that in embryonic renal progenitor cells (C3H10T1/2 cell line), treatment with this substance can significantly increase BMP2 mRNA and protein levels, while enhancing BMP2 promoter activity. This effect completely disappears in GPR54 gene knockout cells, confirming the specificity of receptor-mediated signaling pathways.

The GPR54 signaling axis induces osteoblast differentiation through the BMP2 dependent pathway, which is highly correlated with the mesenchymal epithelial transition (MET) process during renal development. BMP2 upregulates the expression of osteogenic related genes such as Runx2 and DLX5 by activating the SMAD1/5/9 phosphorylation cascade.

During embryonic kidney development, this process promotes the differentiation of renal mesenchymal cells into glomerular mesangial cells and tubular epithelial cells. It is worth noting that the BMP2 secretion induced by it has a paracrine effect, and the treated cell culture medium can stimulate osteogenic differentiation of GPR54 wild-type cells, but is ineffective against GPR54 knockout cells, further confirming the integrity requirement of the signaling pathway.

Based on its regulatory role in embryonic kidney development, its clinical potential is mainly reflected in two aspects:

Early diagnosis of congenital renal abnormalities: Studies have found a significant correlation between concentration levels and the benign or malignant nature of small renal masses (SRMs). By detecting the levels of this substance in amniotic fluid or maternal serum, early screening for congenital kidney developmental abnormalities may be achieved.

Renal regenerative medicine: In vitro culture systems, it can promote the proliferation and differentiation of renal progenitor cells, providing a new induction strategy for tissue engineering kidney construction. For example, combining it with BMP2 in biological scaffold materials can significantly improve the efficiency of renal tubular structure formation.

It is a key initiating factor of the hypothalamic pituitary gonadal axis (HPG axis), and its mechanism of action is achieved through the following steps:

GnRH pulse generator activation: Stimulates hypothalamic arcuate nucleus and preoptic area neurons through GPR54 receptors, inducing pulsatile secretion of gonadotropin-releasing hormone (GnRH). This pulse frequency directly determines the release pattern of luteinizing hormone (LH) and follicle stimulating hormone (FSH) by the pituitary gland.

Maintenance of gonadal function: After puberty, the secretion of GnRH is continuously regulated to maintain the steady-state levels of gonadal hormones (estrogen, progesterone, testosterone). Animal experiments have shown that KISS1 gene knockout mice exhibit puberty loss and infertility, while exogenous kisspeptin injection can restore their reproductive function.

Hypothalamic amenorrhea and hypogonadism: providing physiological alternative treatment options for such diseases. In clinical trials, a single intravenous injection of Kisspeptin-10 (3.2 nmol/kg) significantly stimulated LH secretion in healthy women (peak value exceeding 5 times baseline), and the effect lasted for more than 6 hours. For infertility patients caused by hypothalamic dysfunction, periodic administration can reconstruct a regular GnRH pulse secretion pattern.

Polycystic ovary syndrome (PCOS): PCOS patients often have abnormal GPR54 signaling. Research has found that the serum level of Kisspeptin-10 in PCOS patients is significantly lower than that in healthy controls, and is negatively correlated with the LH/FSH ratio. In response to this mechanism, analogs have been developed as potential therapeutic strategies aimed at improving ovulation function by restoring GnRH pulse rhythm.

New ovulation triggering strategy: Traditional hCG triggering poses a risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) cycles. By precisely regulating the LH peak, the incidence of OHSS can be reduced. A clinical trial involving 50 patients showed that the ovulation rate triggered by Kisspeptin (6.4 nmol/kg) was comparable to that of the hCG group (92% vs 94%), but the incidence of severe OHSS was significantly reduced (0% vs 12%).

Embryo implantation window regulation: By regulating the expression of endometrial receptivity related genes (such as HOXA10, LIF), the embryo implantation environment is optimized. Animal experiments have shown that treatment can increase the blood flow of endometrial spiral arteries and upregulate the expression of β 3, thereby improving embryo implantation rate.

Hormone dependent tumor treatment: inhibit the growth of hormone dependent tumors such as breast cancer and prostate cancer through GPR54 receptor. Mechanism studies have shown that it can block the estrogen receptor (ER) signaling pathway and induce tumor cell apoptosis. In the breast cancer model, the combination of tamoxifen treatment can significantly delay the tumor progression (inhibition rate of 65%).

Exploration of metastasis inhibition mechanism: Kisspeptin-10 inhibits tumor cell invasion by downregulating the expression of matrix metalloproteinase-2/9. The melanoma cell line experiment showed that treatment can reduce cell migration rate by more than 50% and reduce the formation of lung metastatic nodules.